Therapeutic 188Re-lanreotide: Determination of radiopharmacokinetic parameters in rats

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 4, 2010, Pages 456-461

  Molina Trinidad, Eva M ^a,c   De Murphy, Consuelo Arteaga ^d   Jung Cook, Helgi ^b   Stack, Eduardo Murphy ^e   Pedraza Lopez, Martha ^d   Morales Marquez, José Luis ^a   Serrano, Guadalupe Vertiz ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e Universidad Westhill   (Mexico)

Author keywords

Radiopharmacokinetics; Two compartment pharmacokinetics

Indexed keywords

LANREOTIDE RE 188; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; RADIOISOTOPE; RHENIUM; SOMATOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SCINTISCANNING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; IMAGE ANALYSIS; IMAGE QUALITY; LIVER CELL CARCINOMA; LIVER SCINTISCANNING; MALE; MEAN RESIDENCE TIME; NONHUMAN; RAT; STEADY STATE; TISSUE DISTRIBUTION; ANIMAL; BONE; HALF LIFE TIME; LIVER; LIVER TUMOR; METABOLISM; MUSCLE; REFERENCE VALUE; SCINTISCANNING; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; CARCINOMA, HEPATOCELLULAR; HALF-LIFE; LIVER; LIVER NEOPLASMS; MALE; MUSCLES; PEPTIDES, CYCLIC; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; REFERENCE VALUES; RHENIUM; SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 85047681483     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.04.0007     Document Type: Article

References (29)

1. 3-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 1993 20 : 716 731.
2. Reubi JC et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and therapeutic use Eur J Nucl Med 2000 27 : 273 282.
3. Virgolini I et al. In and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Semin Nucl Med 2002 32 : 148 155.
4. Virgolini I et al. Nuclear medicine in the detection and management of pancreatic islet-cell tumours Clin Endocrinol Metab 2005 19 : 213 227.
5. Susini C, Buscail L Rationale for the use of somatostatin analogs as antitumor agents Ann Oncol 2006 17 : 1733 1742.
6. 67Ga citrate scintigraphy for visualization of extranodal marginal zone B cell lymphoma of the MALT type: a comparative study Eur J Nucl Med Mol Imaging 2003 30 : 1087 1095.
7. Pawlikowski M, Melen-Mucha GM Perspectives of new potential therapeutic applications of somatostatin analogs Neuroendocrinol Lett 2003 24 : 21 27.
8. 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG-PET Eur J Nucl Med Mol Imaging 2005 32 : 1144 1151.
9. 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 2006 33 : 532 540.
10. 111In-DOTA-Dphe1-Tyr3-octreotide and chromogram in A assay in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 2008 35 : 1796 1802.
11. 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in vitro and in vivo results Melanoma Res 2005 15 : 523 529.
12. Knapp FF et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium 188-labeled radiopharmaceuticals for cancer treatment Anticancer Res 1997 17 : 1783 1795.
13. 188Re Radiochim Acta 1997 79 : 63 70.
14. 188Re-labeled MoAb ior CEAI and its F(ab')2 fragment by avidin-biotin strategy Nucl Med Biol 1999 26 : 57 62.
15. Meléndez AL et al. Labeling peptides with rhenium-188 Int J Pharm 1999 182 : 165 172.
16. García SL et al. Uptake of the 188Re(V)-DMSA complex by cervical carcinoma cells in nude mice: pharmacokinetics and dosimetry Appl Radiat Isotop 2001 54 : 413 418.
17. 188Re-β-naphthyl- peptide in cervical carcinoma tumours in athymic mice Nucl Med Biol 2001 28 : 319 326.
18. 188Re-lanreotide in athymic mice with induced human cancer tumors Int J Pharm 2006 310 : 125 130.
19. Gabriel M et al. 68Ga-DOTA-Tyr3-octreotide-PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 2007 48 : 508 518.
20. Yau T et al. Evolution of systemic therapy of advanced hepatocellular carcinoma World J Gastroenterol 2008 14 : 6437 6441.
21. Villanueva SO, Hernández GR. Manual en Ciencias de los Animales de Laboratorio. INCMNSZ
22. Correa GL et al. Uptake of 153Sm-DTPA-bis-biotin and 99mTc-DTPA-bis- biotin in rat AS-30D-hepatoma cells Nucl Med Biol 2003 30 : 135 140.
23. Kroker R et al. The lack of active bile acid transport in AS-30D ascites hepatoma cells Naunyn Schmiedebergs Arch Pharmacol 1978 303 : 299 301.
24. Masuno H et al. Isolation of lipolytic factor (toxohormone-L) from ascites fluid of patients with hepatoma and its effects on feeding behavior Eur J Cancer Clin Oncol 1984 20 : 1177 1185.
25. Reubi JC et al. Inmunohistochemical localization of somatostatin receptors sst2A in human tumors Am J Pathol 1998 153 : 233 245.
26. Reynaert H et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma Gut 2007 53 : 1180 1189.
27. Li Y et al. Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice World J Gastroenterol 2005 11 : 3953 3957.
28. Li G et al. Antitumor effect mediated by coexpression of somatostatin receptor type 2 and cytosine deaminase on nude mice xenografts J US China Med Sci 2006 3 : 35 39.
29. Laster M et al. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238 J Hepatol 2005 42 : 230 237.